key: cord-1022084-9akorq8l
authors: Du, Shuo; Cao, Yunlong; Zhu, Qinyu; Yu, Pin; Qi, Feifei; Wang, Guopeng; Du, Xiaoxia; Bao, Linlin; Deng, Wei; Zhu, Hua; Liu, Jiangning; Nie, Jianhui; Zheng, Yinghui; Liang, Haoyu; Liu, Ruixue; Gong, Shuran; Xu, Hua; Yisimayi, Ayijiang; Lv, Qi; Wang, Bo; He, Runsheng; Han, Yunlin; Zhao, Wenjie; Bai, Yali; Qu, Yajin; Gao, Xiang; Ji, Chenggong; Wang, Qisheng; Gao, Ning; Huang, Weijin; Wang, Youchun; Xie, X. Sunney; Su, Xiao-dong; Xiao, Junyu; Qin, Chuan
title: Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy
date: 2020-09-14
journal: Cell
DOI: 10.1016/j.cell.2020.09.035
sha: a4c20234200ba862666771ab44e985c9559cad0b
doc_id: 1022084
cord_uid: 9akorq8l

Understanding how potent neutralizing antibodies (NAbs) inhibit SARS-CoV-2 is critical for effective therapeutic development. We previously described BD-368-2, a SARS-CoV-2 NAb with high potency; however, its neutralization mechanism is largely unknown. Here we report the 3.5-Å cryo-EM structure of BD-368-2/trimeric-spike complex, revealing that BD-368-2 fully blocks ACE2 recognition by occupying all three receptor-binding domains (RBDs) simultaneously, regardless of their “up” or “down” conformations. Also, BD-368-2 treats infected adult hamsters at low dosages and at various administering windows, in contrast to placebo hamsters that manifested severe interstitial pneumonia. Moreover, BD-368-2’s epitope completely avoids the common binding site of VH3-53/VH3-66 recurrent NAbs, evidenced by tripartite co-crystal structures with RBD. Pairing BD-368-2 with a potent recurrent NAb neutralizes SARS-CoV-2 pseudovirus at pM level and rescues mutation-induced neutralization escapes. Together, our results rationalized a new RBD epitope that leads to high neutralization potency and demonstrated BD-368-2’s therapeutic potential in treating COVID-19.

Coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic (Callaway et al., 2020 ). An essential structural protein of SARS-CoV-2 is the Spike (S) protein, which recognizes human angiotensin-converting enzyme 2 (ACE2) to mediate the fusion between viral and host cell membranes (Hoffmann et al., 2020; Walls et al., 2020) . The S protein could be divided into two regions, S1 and S2. S1 contains the N-terminal domain (NTD), which likely contributes to maintaining the prefusion state of the S protein, and the receptorbinding domain (RBD), which is responsible for interacting with ACE2 (Lan et al., 2020; Shang et al., 2020; Wang et al., 2020b; Xu et al., 2020; Zhou et al., 2020b) . Binding of ACE2 to RBD induces a conformational change in the S protein, leading to the exposure of the membrane fusion peptide in S2 that subsequently functions in the membrane fusion process. Structural analyses of the S trimer reveals that RBDs could adopt different "up" and "down" conformations Walls et al., 2020; Wrapp et al., 2020) , which has important implications in both receptor binding and immune recognition.

Potent neutralizing antibodies (NAbs) have high potential to be widely served as prophylactics and therapeutics for COVID-19. SARS-CoV-2 neutralizing antibodies (NAbs) targeting the RBD, as well as the NTD, were reported extensively (Barnes et al., 2020; Brouwer et al., 2020; Cao et al., 2020; Chi et al., 2020; Hansen et al., 2020; Ju et al., 2020; Pinto et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Seydoux et al., 2020; Shi et al., 2020; Wang et al., 2020a; Wec et al., 2020; Wu et al., 2020; Zhou et al., 2020a) . Recently, we identified a series of potent NAbs from convalescent patients using high-throughput single-cell RNA sequencing (Cao et al., 2020) . One of them, BD-368-2, is among the most potent SARS-CoV-2 NAbs identified, exhibiting an IC 50 of 1.2 and 15 ng/mL against pseudotyped and authentic SARS-CoV-2, respectively. BD-368-2 also showed high therapeutic and prophylactic efficacy in hACE2-transgenic mice infected by SARS-CoV-2, although the placebo mice would only J o u r n a l P r e -p r o o f display a mild course of the disease . The high potency of BD-368-2 suggests a neutralization mechanism different than other NAbs.

In this study, we first investigated BD-368-2's neutralizing mechanism and its molecular interaction with the S protein, through structural characterizations by high-resolution cryo-electron microscopy (cryo-EM) and crystallography. Using a prefusion-statestabilized S trimer, we determined the 3.5-Å cryo-EM structure of the antigen-binding fragments (Fabs) of BD-368-2 in complex with the S trimer and showed that BD-368-2 fully blocks ACE2 binding by occupying all three RBDs simultaneously regardless of their "up" or "down" conformations. The high neutralization potency and in vivo therapeutic efficacy of BD-368-2 were further confirmed by administering BD-368-2 with various dose windows and dosages to SARS-CoV-2 infected adult hamsters. Unlike hACE2 mice and rhesus macaque, the hamster model used in this study developed severe interstitial pneumonia with over 80% of the lung sections displaying lesions, when no intervention was taken Cao et al., 2020; Chandrashekar et al., 2020; Corbett et al., 2020; Deng et al., 2020; Imai et al., 2020; Munster et al., 2020; Rogers et al., 2020; Shan et al., 2020; Sia et al., 2020; van Doremalen et al., 2020; Yu et al., 2020) . The severity of hamsters' lung inflammation was effectively reduced when given BD-368-2 at low dosages and at various administering windows.

Furthermore, we obtained a large collection of VH3-53/VH3-66 derived recurrent NAbs and showed that their common epitopes are entirely non-overlapping with that of BD-368-2, evidenced by the tripartite crystal structures of RBD in complex with their Fabs.

An antibody cocktail consisted of BD-368-2 and a potent recurrent NAb, BD-629, could neutralize wildtype SARS-CoV-2 pseudovirus at pM level, while at the same time neutralize escaping mutants bearing mutations in the RBD . These results rationalized the potent neutralizing mechanism of BD-368-2, presented a new potent cocktail design to rescue mutation-induced neutralization escape, and demonstrated the effective therapeutic application of BD-368-2 in an animal model with severe COVID-19 symptoms.

J o u r n a l P r e -p r o o f

To investigate the molecular mechanism by which BD-368-2 neutralizes SARS-CoV-2, we set to characterizing its interaction with the S trimer using cryo-EM. We first used the 2P variant of the S protein (S2P) that contains two stabilizing proline substitutions at residues 986-987 . However, BD-368-2's Fab promptly disrupted the structural integrity of S2P ( Figure 1A ). This phenomenon is reminiscent of S230, a SARS-CoV NAb, which promotes a fusogenic-like conformational rearrangement of SARS-CoV S (Walls et al., 2019) . We then produced S-HexaPro (S6P), which has a more stabilized prefusion structure due to the introduction of four additional proline substitutions in the S2 segment (Hsieh et al., 2020) . Indeed, S6P is more stable in the presence of BD-368-2, enabling homologous sample preparation for cryo-EM imaging ( Figure 1A) . We subsequently determined the cryo-EM structure of BD-368-2 Fab in complex with S6P at an overall resolution of 3.5-Å ( Figure S1 , Table S1 ).

S6P exhibits an asymmetric conformation as previously observed (Hsieh et al., 2020; Wrapp et al., 2020) , with one RBD "up" and two RBDs "down" ( Figure 1B ). BD-368-2 recognizes an epitope in a far corner that is accessible in both the "up" and "down" RBDs, and therefore all three RBDs in the S trimer are engaged by the Fabs of BD-368-2 simultaneously. This is in sharp contrast to the VH3-53/VH3-66 derived NAbs described below, which could only bind to the RBDs in the "up" conformation, since binding to the "down" RBDs would be sterically hindered by the adjacent protomer. The epitope of BD-368-2 does not overlap with the binding site of ACE2 on RBD to a large extent; however, a structural superimposition of the RBD/BD-368-2 and RBD/ACE2 complexes reveals a clash between the VL domain of BD-368-2 Fab and ACE2 ( Figure 1C ), consistent with our previous analyses that BD-368-2 competitively inhibits the interaction between RBD and ACE2 (Cao et al., 2020) . Also, ACE2 can exist as a homodimer in vivo , and the constant domains in the BD-368-2 Fab may substantially clash with the other ACE2 protomer in the ACE2 dimer as well ( Figure 1C ). Collectively, these J o u r n a l P r e -p r o o f structural analyses demonstrated that BD-368-2 could achieve full occupancy of the RBDs on S trimer and blocks all possible binding sites of ACE2, thereby exerting an high potent neutralization effect.

Previously, we demonstrated that BD-368-2 could effectively provide therapeutic interventions and prophylactic protection against SARS-COV-2 in the hACE2 mice model. However, the hACE2 mice model only exhibits mild pneumonia, similar to rhesus macaque, which does not fully reflect the diverse settings of humans infections. On the other hand, golden hamsters, especially adult hamsters, may present severe interstitial pneumonia accompanied by immense body weight loss (Imai et al., 2020; Sia et al., 2020) . Thus, it is of high value to evaluate BD-368-2's in vivo efficacy in the severe hamster model to investigate whether potent neutralization antibodies could ameliorate human COVID-19 patients that tend to develop severe clinical symptoms.

Older hamsters present much more severe pneumonia when infected by SARS-CoV-2 compared to younger hamsters (Imai et al., 2020) . To better mimic the settings of severe human infections, we utilized 4-month-old adult hamsters that were inoculated intranasally with authentic SARS-CoV-2 stock virus at 1×10 5 TCID 50 to evaluate BD-368-2's therapeutic potential. 20 mg/kg of BD-368-2 was given to SARS-CoV-2 infected hamsters with various administering windows starting from 24 hours pre-infection to 48 hours post-infection ( Figure 2A ). Each hamster's clinical manifestations and body weight were monitored and recorded daily over a period of 7 days. The hamsters were sacrificed at day 7, and the lungs were collected for viral load analyses and pathological examinations. Indeed, placebo hamsters exhibited severe interstitial pneumonia accompanied by high lung viral titers and immense weight loss ( Figure 2B ). At day 7, histological analyses of lung sections from placebo hamsters displayed diffuse lesions, characterized by severe thickened alveolar septa and infiltration of inflammatory cells in over 80% of the alveolar cavities ( Figure 3A ). The alveolar septa were filled with J o u r n a l P r e -p r o o f macrophages and lymphocytes. Peribronchial and perivascular inflammation were also observed, along with exudative bronchitis.

On the contrary, hamsters that were given BD-368-2 all showed an effective reduction in total weight loss, viral load, and pneumonia severity, except for the 48 hpi group, which only showed slight amelioration ( Figures 2B, 2C , 2D, and 2E). Infected hamsters given BD-368-2 at -24 hpi, 2 hpi, 8 hpi, and 24 hpi displayed mild interstitial pneumonia, with rare or no peribronchial and perivascular inflammation identified ( Figure 3 ). Hamsters administered 20 mg/kg BD-368-2 at 48 hpi progressed into moderate or severe interstitial pneumonia, with lesions covering on average 60% of the lung sections ( Figure 3F ).

Together, we demonstrated that BD-368-2 shows high prophylactic and therapeutic efficacy in SARS-CoV-2 infected hamsters at various administering windows. However, it is clear that late administering windows would hinder BD-368-2's ability to stop pneumonia development. This observation suggests that NAb therapy given at late time points may not exhibit high efficacy in COVID-19 patients, or at least for those who tend to manifest severe clinical symptoms.

Next, we asked whether BD-368-2 could treat SARS-CoV-2 infected hamsters at lower dosages. Three additional dosages, 10 mg/kg, 5 mg/kg, and 2 mg/kg BD-368-2 were given at 2 hpi to evaluate their therapeutic efficacy ( Figure 4A ). All dosages showed a reduction of viral load and weight loss of SARS-CoV-2 infected hamsters ( Figure 4 ).

Dosage of 10 mg/kg and 5 mg/kg both showed great improvement of inflammation ( Figure 5 ). However, 2 mg/kg BD-368-2 did not effectively stop pneumonia development, resulted in displaying moderate or severe interstitial pneumonia ( Figure 5E ). Summing up, our data demonstrated that BD-368-2 could effectively treat infected adult hamsters at low dosages and at various administering windows, compared to placebo hamsters that manifested severe interstitial pneumonia.

Since SARS-CoV-2 is continuously gaining mutations (Dawood, 2020; Korber et al., 2020; Saha et al., 2020; Sheikh et al., 2020; van Dorp et al., 2020) , concerns about mutation-induced neutralization escape have been raised, which make it crucial to have a potent pair of NAbs as a cocktail for therapy (Baum et al., 2020; Hansen et al., 2020) .

The unique epitope of BD-368-2, which lies in the far corner of RBD, suggests that BD-368-2 could be easily paired with other RBD-binding NAbs. However, due to BD-368-2's high potency, effective pairing requires a non-overlapping NAb that exhibits near or at least close to pM level neutralization potency, which is absent in our previous NAb collection.

To obtain such a potent NAb, we turned our attention to the stereotypic/recurrent VH3-53/VH3-66 derived NAbs discovered by us and other groups, since those NAbs have highly similar epitopes and likely avoids the binding site of BD-368-2 ( Barnes et al., 2020; Hansen et al., 2020; Kim et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Yuan et al., 2020a) . We synthesized 28 additional VH3-53/VH3-66 derived antibodies from the RBD-enriched high-throughput single-cell sequencing library previously generated, with all antibodies selected based solely on their variable (V), diversity (D), and joining (J) combinations, which contain a VH3-53/VH3-66 VH and a JH4/JH6 JH.

Combined with our previously reported antibodies, including BD-236, a total of 45 VH3-53/VH3-66 derived antibodies were collected (Table S2 ). Nearly two-thirds of the VH3-53/VH3-66 antibodies displayed neutralizing abilities against SARS-CoV-2 pseudovirus.

Seven new highly potent NAbs were discovered, all showing IC 50 below 20 ng/mL and high binding affinities for RBD ( Figures 6A and S2 ). We also determined the crystal structures of RBD in complexes with the Fabs of several potent VH3-53/VH3-66 NAbs, including BD-236, BD-604, and BD-629 (Table S3) (Table S3) . These tripartite complexes, such as BD-368-2/RBD/BD-629, display Y-like shapes, with the Fabs of BD-368-2 and VH3-53/VH3-66 NAbs attacking the RBD from opposite sides ( Figures 6B, S4A , and S4B). Five regions in BD-368-2 are involved in interacting with RBD: heavy chain CDRH1 and CDRH3, the DE loop in the VH domain, and light chain CDRL1 and CDRL2 ( Figure 6C ). The remaining two CDRs, especially CDRH2, do not directly contact RBD, suggesting that the interaction between BD-368-2 and RBD could be further enhanced by structure-based protein engineering. Among the prominent interactions, Gly26, Phe27, and Ala28 together cradle Tyr449 S (superscript S indicates S protein residues, Figure 6D ). Tyr32 and Arg102 form robust packing with Phe490 S . Arg102 also attaches to Glu484 S via a bidentate interaction. The light chain of BD-368-2 mainly plays a supportive role in stabilizing the conformation of the heavy chain residues. Direct interactions between the light chain and RBD are seen between Asn33, Tyr35, Tyr37, Leu55, and Val483 S ( Figure 6E ). The interactions between the VH3-53/VH3-66 Fabs and RBD are similar to those seen in the respective binary complexes, involving all three heavy chain CDRs (CDRH1-3) and two light chain CDRs (CDRL1, CDRL3) ( Figure S4C ). Two aromatic clusters are particularly crucial for the interaction between BD-629 and RBD. The first involves CDRH1 Tyr33 and CDRH2 Tyr52 and Tyr58, which form hydrogen bond and van der Waals interactions with Thr415 S , Gly416 S , and Lys417 S ( Figure S4D ). The second involves CDRH1 Phe27 and four CDRH3 Tyr, which together bury Tyr453 S , Phe456 S , Phe486 S , and Tyr489 S ( Figure   S4E ). Together, these analyses provided further atomic insights into the critical interactions between BD-368-2 and RBD, and demonstrated that the epitopes of BD-368-2 and the VH3-53/VH3-66 NAbs are entirely non-overlapping.

To evaluate the ability of the cocktail involving BD-368-2 to rescue mutation-induced neutralization escapes, we mixed BD-368-2 and a potent VH3-53/VH3-66 NAb, BD-629, with a 1:1 ratio and performed neutralization assays using pseudoviruses expressing wildtype or various naturally occurring mutants of the S protein . Four naturally occurring variants, L452R, V483A, V483I, and F490L were tested since Leu452, Val483, and Phe490 are critically involved in the BD-368-2/RBD binding interface ( Figures 6D and 6E) . Indeed, L452R, V483A, and F490L exhibited resistance to BD-368-2 ( Figure 7A ). The L452R and F490L mutations would decrease the interaction between RBD and the VH domain of BD-368-2, whereas the V483A substitution would reduce the binding to the VL domain ( Figures 6D and 6E ). BD-629 and the BD-368-2/BD-629 combination could effectively neutralize these mutants ( Figure 7A ).

Furthermore, the BD-368-2/BD-629 combination neutralizes at pM level (9.3 pM, Figure   7B ). Together, these results laid a strong foundation for BD-368-2/BD-629 to serve as an effective paired NAbs therapeutics.

Here we performed comprehensive structural analyses on the neutralizing mechanism of BD-368-2. We show that BD-368-2 binds to the RBDs regardless of their "up" or "down" states, blocks the engagement of ACE2, and causes drastic conformational changes of the S trimer. All these effects likely contribute to its potent neutralizing activity. We further show that the epitopes of BD-368-2 and the VH3-53/VH3-66 NAbs have no overlaps, and can engage one RBD simultaneously. Pairing BD-368-2 with a potent recurrent NAb, BD-629, can efficiently neutralize several naturally occurring S mutants that resist BD-368-2 alone.

Structural analyses suggest that BD-368-2 interacts with RBD using a similar pose as P2B-2F6, another NAb isolated from a SARS-CoV-2 convalescent patient (Ju et al., 2020) . However, the detailed molecular interactions between them and RBD are different J o u r n a l P r e -p r o o f ( Figure S5A ). Compared to P2B-2F6, BD-368-2 binds to RBD with a higher affinity and displays much more potent neutralizing activities (Cao et al., 2020; Ju et al., 2020) .

Furthermore, BD-368-2 binds to RBD with a slightly different orientation, such that it is entirely non-overlapping with the VH3-53/VH3-66 NAbs. In contrast, P2B-2F6 would overlap with the VH3-53/VH3-66 antibodies partially due to mild steric clashes between their VL domains ( Figure S5B ). Indeed, P2B-2F6 displayed partial competition with P2C-1F11, a VH3-66 NAb (Ju et al., 2020) .

Recently, scientists at Regeneron have described another pair of antibodies, REGN10987 and REGN10933, and showed that their cocktail (REGN-COV2) prevented the generation of escaping mutants using a pseudovirus system (Baum et al., 2020; Hansen et al., 2020) . Structural comparisons suggest that REGN10933 and the VH3-53/VH3-66 recurrent NAbs, such as BD-629, share a similar binding region on the RBD; whereas REGN10987 and BD-368-2 target different regions ( Figures S6A and S6B ). BD-629 can bind to RBD together with REGN10987, whereas BD-368-2 would clash with both REGN10987 and REGN10933 ( Figure S6C ) and therefore can't function in a pair with any of them. Therefore, the BD-368-2/BD-629 cocktail described in this study provides a new pairing strategy that is distinct from REGN-COV2. It is worth noting that in the context of the S trimer, when a BD-368-2 molecule is bound to a "down" RBD, its constant domains may impose some steric hindrance for BD-629 to engage the "up" protomer ( Figure S6D ). Similarly, a REGN10987 molecule interacting with a "down" RBD could also interfere with the binding of REGN10933 to the "up" RBD ( Figure S6E ).

In case of the BD-368-2/BD-629 pair, we envision that this issue could be easily resolved by a slight elbow motion of either BD-368-2 or BD-629, since the steric hinderance is quite modest. Furthermore, BD-368-2 can cause drastic conformational changes of the S trimer ( Figure 1A ), which may also facilitate the binding of BD-629. In any event, the trimeric architecture and dynamic nature of the S protein should be considered when potential combination of different NAbs are evaluated.

Besides the VH3-53/VH3-66 antibodies, further structural analyses suggest that BD-368-2 appears to be able to bind RBD together with two other antibodies: S309 and CR3022 J o u r n a l P r e -p r o o f ( Figure S7 ). These antibodies each have a unique epitope and displays distinct binding poses. S309 recognizes a glycan-containing epitope and can also bind both the "up" and "down" RBDs (Pinto et al., 2020) ; however, S309 does not directly compete with ACE2, and likely has a different mechanism of neutralization. CR3022 recognizes an epitope that is inaccessible in the prefusion state of the S protein, and have to engage the RBDs when at least two RBDs are "up" and rotated (Huo et al., 2020; Yuan et al., 2020b) .

Certainly, the SARS-CoV-2 S protein is flexible in nature and exists in multiple conformations, and the presence of some of these antibodies can alter the conformation landscape and trigger conformational changes. Collectively, these distinct antibodies provide an arsenal of therapeutic choices, and multiple combinations between them, even with antibodies that target the NTD of the S protein (Chi et al., 2020; , can be tested to intervene the SARS-CoV-2 pandemic.

Importantly, we showed that BD-368-2 could effectively treat SARS-COV-2 infected Table S2 .

(B) Neutralization potency measured by a SARS-CoV-2 spike-pseudotyped VSV neutralization assay. Data for each NAb were obtained from a representative neutralization experiment, which contains three replicates. Data are represented as mean ± SD. IC 50 and IC 80 were calculated by fitting a four-parameter logistic curve.

J o u r n a l P r e -p r o o f (C) Measurement of the dissociation constant against RBD for the representing NAbs.

All analyses were performed by using a serial 2-fold dilution of purified RBDs, starting from 25 nM (magenta) to 1.56 nM (black). (C) Structural superimposition of the above two complexes suggests that BD-629 can bind to RBD together with REGN10987, whereas BD-368-2 would clash with both REGN10987 and REGN10933 and therefore can't function in a pair with any of them.

(D) When a BD-368-2 molecule is bound to a "down" RBD in the S trimer, its constant domains may impose some steric hindrance for BD-629 to engage the "up" protomer.

(E) A REGN10987 molecule interacting with a "down" RBD could also interfere with the binding of REGN10933 to the "up" RBD. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Chuan Qin, qinchuan@pumc.edu.cn (C.Q.)

There are restrictions on the availability of antibodies due to limited stock and continued consumption. We are glad to share the remaining antibodies with reasonable compensation for processing and shipping upon completion of a Material/Data Transfer Agreement for non-commercial usage.

The crystal structures of RBD in complex with the Fabs of BD-236, BD-604, BD-629, BD-236/BD-368-2, BD-604/BD-368-2, and BD-629/BD-368-2 have been deposited in the PDB with accession codes of 7CHB, 7CH4, 7CH5, 7CHE, 7CHF, and 7CHC, respectively. The cryo-EM map and atomic coordinates of the S6P in complex with BD-368-2 have been deposited in the EMDB and PDB with accession codes EMD-30374 and 7CHH, respectively. All antibody sequences used in this study can be found in Table S2 .

Additional Supplemental Items are available from Mendeley Data at http://dx.doi.org/10.17632/ssxn5c6k59.1.

The SARS-CoV-2 wildtype pseudovirus was constructed as previously described using VSV pseudotyped virus (G*∆G-VSV) and SARS-CoV-2 strain Wuhan-Hu-1 (GenBank: MN908947) . The mutated pseudovirus was constructed by site-directed mutagenesis followed by transformation of E. coli DH5α competent cells .

The authentic SARS-CoV-2 virus SARS-CoV-2/WH-09/human/2020/CHN was used in this study. Experiments associated with the authentic virus were conducted in a biosafety level 3 (ABSL3) facility using HEPA-filtered isolators.

Pathogen-free, male, and female golden hamsters were obtained from BEIJING HFK BIOSCIENCE. The hamsters are used in this study were 14-16 weeks old and the weight varied from 180-225g. Murine studies were performed in an animal biosafety level 3 (ABSL3) facility using HEPA-filtered isolators. All procedures in this study involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Institute of Laboratory Animal Science, Peking Union Medical College (BLL20001).

All antibody sequences in this manuscript were generated in the previous study (Cao et al., 2020) . The antibodies were in vitro expressed using HEK293 cells. Briefly, the selected antibodies' heavy and light chain VDJ cDNA were codon-optimized and cloned into vectors containing human IgG1 constant regions. IgG monoclonal antibodies were obtained by transfecting HEK293 cells with heavy and light chain plasmids at a 1:1 ratio, J o u r n a l P r e -p r o o f followed by SDS-PAGE analyses. The SARS-COV-2 binding specificities of the antibodies were quantity by ELISA against the Spike protein and the RBD protein.

Briefly, ELISA plates were coated by Spike or RBD proteins at 1 µg/mL and 0.01 µg/mL in PBS at 4°C overnight. After standard blocking and washing, 100 µL monoclonal antibody at 1 µg/mL was added and incubated at room temperature for 2 hours. After the incubation, the plates were washed and incubated with goat anti-human IgG (H+L)/HRP for 1 hour at room temperature with a concentration of 0.08 µg/mL. The absorbance at 450 nm was measured by a microplate reader after the chromogen solution was added.

An antibody is defined as ELISA-positive when the OD 450 is saturated using 1 µg/mL RBD/Spike proteins.

The dissociation coefficients for the binding between antibodies and SARS-CoV-2 RBD were measured using a Biacore T200 (GE Healthcare). Antibodies were Captured to ~50-100 RU Via FC-capture on a Series S Sensor Protein A Chip (GE Healthcare). Serial dilutions of purified SARS-CoV-2 RBD were then injected, ranging in concentrations from 25 to 1.56 nM (2-fold dilutions). The running buffer is 0.01 M HEPES, pH 7.4, supplemented with 0.005% (v/v) P20. The resulting data were fit to a 1:1 binding model using the Biacore Evaluation Software.

The pseudovirus neutralization assays were performed using Huh-7 cell lines (Cao et al., 2020) . Briefly, various concentrations of antibodies (3-fold serial dilution using DMEM) were mixed with the same volume of SARS-CoV-2 pseudovirus in a 96 well-plate. The mixture was incubated for 1 h at 37 °C and supplied with 5% CO 2 . Pre-mixed Huh-7 cells were added to all wells and incubated for 24 h at 37 °C and supplied with 5% CO 2 . After incubation, the supernatants were removed, and D-luciferin reagent (Invitrogen) was added to each well and measured luciferase activity using a microplate spectrophotometer (PerkinElmer EnSight). The inhibition rate is calculated by comparing the OD value to the negative and positive control wells. IC 50 and IC 80 were determined by a fourparameter logistic regression using GraphPad Prism 8.0 (GraphPad Software Inc.).

The SARS-CoV-2 RBD (residues 319-541) with an N-terminal His 6 tag was cloned into a modified pFastBac vector (Invitrogen) that encodes a gp67 signal peptide. Bacmids were generated using the Bac-to-Bac system (Invitrogen). Baculoviruses were generated and amplified using the Sf21 insect cells. For protein production, Hi5 insect cells at 1.5 million cells/mL were infected with the RBD baculovirus. The conditioned media were harvested after 48 h, concentrated using a Hydrosart Ultrafilter, and exchanged into the Fab, BD-368-2 IgG (2 mg/mL) was digested with papain (0.1 mg/mL) for 2 hours at 37 °C, in a buffer containing 50 mM phosphate buffer saline, pH 7.0, 2 mM EDTA, and 5.5 mM cysteine. Digestion was quenched using 30 mM iodoacetamide at 30 °C for 30 min. The Fc region was removed by protein A chromatography, and the BD-368-2 Fab was further purified using the Superdex 200 Increase column and eluted using the final buffer.

The S2P expression construct that encodes the Spike ectodomain (residues 1-1208) with two stabilizing Pro substitutions (residues 986-987) and a "GSAS" substitution at the furin cleavage site (residues 682-685) was previously described (Cao et al., 2020) . The S6P construct containing four additional Pro substitutions (F817P, A892P, A899P, J o u r n a l P r e -p r o o f A942P) (Hsieh et al., 2020) was generated from S2P using a PCR based method. The S2P or S6P plasmid was transfected into the HEK293F cells when the cell density reached 1 million cells/mL and expressed for four days. The S proteins were purified using the Ni-NTA resin, followed by a Superose 6 Increase 10/300 gel filtration column (GE Life Sciences), and eluted using the final buffer.

The For data collection, the crystals were transferred to a solution containing the crystallization solution supplemented with 20% ethylene glycol or 20% glycerol before they were flash-cooled in liquid nitrogen. Diffraction data were collected at the Shanghai Synchrotron Radiation Facility (beamline BL17U) and the National Facility for Protein Science Shanghai (beamline BL19U). The data were processed using HKL2000 (HKL J o u r n a l P r e -p r o o f Research). All structures were solved by the molecular replacement method using the Phaser program (McCoy et al., 2007) in Phenix (Liebschner et al., 2019) . The structural models were then manually adjusted in Coot (Emsley et al., 2010) and refined using Phenix.

For the negative-staining study, S2P, S6P, and BD-368-2 Fab were diluted to 0.02 mg/ml using 25 mM HEPES, pH 7.2, 150 mM NaCl. BD-368-2 Fab was then mixed with S2P or S6P in a 1:1 volume ratio and incubated on ice for 3 min or at room temperature for 30 min. The mixture was then applied onto a glow-discharged carbon-coated copper grid (Zhong Jing Ke Yi, Beijing). After 1 min, the excess liquid was removed using a filter paper. The grids were then stained using 1% uranyl acetate for 30 seconds and air-dried.

A Tecnai G2 20 Twin electron microscope (FEI) operated at 120 kV was used to examine the grids. Images were recorded using a CCD camera (Eagle, FEI).

Holy-carbon gold grids (Quantifoil, R1.2/1.3) were glow-discharged for 30 seconds using a Solarus 950 plasma cleaner (Gatan) with a 4:1 O 2 /H 2 ratio. Four microliter S6P (0.2 mg/mL) and 0.5 microliter BD-368-2 Fab (1.2 mg/mL) were mixed on ice for 1 minute, and then quickly applied onto the glow-discharged grids. Afterward, the girds were blotted with a filter paper (Whatman No. 1) at 4 °C and 100% humidity, and plunged into the liquid ethane using a Vitrobot Mark IV (FEI). The grids were first screened using a 200 kV Talos Arctica microscope equipped with a Ceta camera (FEI). Data collection was carried out using a Titan Krios electron microscope (FEI) operated at 300 kV.

Movies were recorded on a K2 Summit direct electron detector (Gatan) using the SerialEM software (Mastronarde, 2005) , in the super-resolution mode at a nominal magnification of 130,000, with an exposure rate of 7.1875 e-/Å2 per second. A GIF Quantum energy filter (Gatan) with a slit width of 20 eV was used at the end of the detector. The defocus range was set from -0.7 to -1.2 µm. The micrographs were dosefractioned into 32 frames with a total exposure time of 8.32 s and a total electron exposure of 60 electrons per Å 2 . Statistics for data collection are summarized in Table S1 .

The workflow of data processing was illustrated in Figure S1 . A total of 5,273 movie stacks were recorded. Raw movie frames were aligned and averaged into motioncorrected summed images with a pixel size of 1.055 Å by MotionCor2 (Zheng et al., 2017) . The contrast transfer function (CTF) parameters of each motion-corrected image were estimated by the Gctf program (v1.06) (Zhang, 2016) . Relion (v3.07) was used for all the following data processing (Zivanov et al., 2018) . The S trimer (PDB ID: 6VSB) was used as a reference for the 3D classifications. The local resolution map was analyzed using ResMap (Kucukelbir et al., 2014) and displayed using UCSF Chimera (Pettersen et al., 2004) .

The S trimer (PDB ID: 6VSB) and the Fv region of BD-368-2 Fab from the crystal structure described above were docked into the cryo-EM density using UCSF Chimera.

Refinement was performed using the real-space refinement in Phenix. Figures were prepared using Pymol (Schrödinger) and UCSF Chimera.

A total of thirty 14-16 weeks old hamsters were used in this study. The hamsters were inoculated intranasally with the authentic SARS-CoV-2 stock virus with a dosage of 10 5 TCID 50 in 100 µl PBS. The infected hamsters were observed daily to record body weights, clinical symptoms, and responsiveness to external stimuli. The hamsters were sacrificed at 7 dpi, and the lungs were collected for viral load analyses and pathological examinations.

Viral load detection was performed by qRT-PCR. The total RNA of the lungs was extracted from lung homogenate by using the RNeasy Mini Kit (Qiagen). Whole lung homogenates were prepared by using an electric homogenizer. The reverse transcription was performed using the PrimerScript RT Reagent Kit (TaKaRa) with the manufacturers' instructions. qRT-PCR reactions were performed in duplicates using the PowerUp SYBG Green Master Mix Kit (Applied Biosystems), using the following cycling protocol: 50 °C for 2 min, 95 °C for 2 min, followed by 40 cycles at 95 °C for 15 s and 60 °C for 30 s, and then 95 °C for 15 s, 60 °C for 1 min, 95 °C for 45 s. The primer sequences used for J o u r n a l P r e -p r o o f qRT-PCR are as follows: forward: 5′-TCGTTTCGGAAGAGACAGGT-3′, reverse: 5′-GCGCAGTAAGGATGGCTAGT-3′. The standard curve is constructed by using serial tenfold dilutions of a recombinant plasmid with a known copy number (from 1.47 × 10 9 to 1.47 × 10 1 copies per µl). All experiments were performed in a Biosafety Level 3 facility.

Autopsies were performed in the animal biosafety level 3 (ABSL3) laboratory. Lungs were grossly examined and then fixed in 10% buffered formalin solution, and paraffin sections (3-4 µm in thickness) were prepared. H&E stain, periodic acid-Schiff (PAS) stain, and modified Masson's Trichrome stain were used to identify histopathological changes in hamster lungs.

GraphPad Prism 8 was used for fitting the four-parameter logistic curves and calculating the IC 50 and IC 80 for all neutralization assays. The inhibition rates were indicated as mean ± SD. K D values were fit to a 1:1 binding model by using the Biacore Evaluation Software following the manufacturer's instructions.

Viral load results for each hamster's lung were expressed as log 10 -transformed numbers of genome equivalent copies per ml by comparing the C t values to the standard curves.

One-tailed t-test was used to analyze the differences in viral load between groups. A Pvalue of less than 0.05 was considered to be significant (* p<0.05, ** p<0.01). All statistical details can be found in figure legends ( Figure 2C ; Figure 4C ). The viral loads were indicated as mean ± SD. J o u r n a l P r e -p r o o f Supplemental table legends   Table S1 . Cryo-EM data collection, processing and validation statistics, Related to 

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

The coronavirus pandemic in five powerful charts

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Mutated COVID-19 may foretell a great risk for mankind in the future

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

Features and development of Coot

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

Structural basis for potent neutralization of SARS-CoV-2 and role of J o u r n a l P r e -p r o o f antibody affinity maturation. bioRxiv

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Structures, conformations and distributions of SARS-CoV-2 spike protein trimers on intact virions. bioRxiv

Stereotypic Neutralizing VH Clonotypes Against SARS-CoV-2 RBD in COVID-19 Patients and the Healthy Population. bioRxiv

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19

Quantifying the local resolution of cryo-EM density maps

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

X-rays, neutrons and electrons: recent developments in Phenix

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Automated electron microscope tomography using robust prediction of specimen movements

Phaser crystallographic software

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

UCSF Chimera--a visualization system for exploratory research and analysis

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques

Structural basis of receptor recognition by SARS-CoV-2

Emerging genetic diversity among clinical isolates of SARS-CoV-2: Lessons for today

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Emergence of genomic diversity and recurrent mutations in SARS-CoV-2

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion

A human monoclonal antibody blocking SARS-CoV-2 infection

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. bioRxiv

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Structural basis of a shared antibody response to SARS-CoV-2

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Gctf: Real-time CTF determination and correction

MotionCor2: anisotropic correction of beam-induced motion for improved cryoelectron microscopy

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

A pH-dependent switch mediates conformational masking of SARS-CoV-2 spike. bioRxiv

We thank the staff of the Shanghai Synchrotron Radiation Facility (beamline BL17U) and the National Facility for Protein Science Shanghai (beamline BL19U) for assistance with X-ray data collection; the Core Facilities at the School of Life Sciences, Peking University for help with crystal screening and negative-staining EM; the Cryo-EM Platform of Peking University for the assistance with EM data collection; the High-